| scholarly article | Q13442814 |
| P2093 | author name string | Yoshiki Sugimura | |
| Yuji Ogura | |||
| Tetsuya Imamura | |||
| Hideki Kanda | |||
| Kenichiro Ishii | |||
| Kiminobu Arima | |||
| Masahiro Kanai | |||
| P2860 | cites work | Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals | Q24314293 |
| Global cancer statistics, 2002 | Q27860562 | ||
| The retinoblastoma protein and cell cycle control | Q27860722 | ||
| CDK inhibitors: positive and negative regulators of G1-phase progression | Q27860983 | ||
| A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction | Q28377593 | ||
| P53, cell cycle control and apoptosis: Implications for cancer | Q28611435 | ||
| Inhibitors of mammalian G1 cyclin-dependent kinases | Q29547907 | ||
| The development of androgen-independent prostate cancer | Q29615650 | ||
| Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors | Q29616203 | ||
| Radiation-induced cell cycle arrest compromised by p21 deficiency | Q29620237 | ||
| Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells | Q32084034 | ||
| Benign prostatic hyperplasia: an overview | Q33545587 | ||
| Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence | Q33940209 | ||
| Differential regulation of the cell cycle by alpha1-adrenergic receptor subtypes | Q34339091 | ||
| The influence of finasteride on the development of prostate cancer | Q34534815 | ||
| The management of high risk prostate cancer | Q35138577 | ||
| Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia | Q35651301 | ||
| Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists | Q36116544 | ||
| Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction | Q36648945 | ||
| Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study | Q39353700 | ||
| Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project | Q39370461 | ||
| Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension | Q39469038 | ||
| Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway | Q40333039 | ||
| Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenorecepto | Q40348607 | ||
| p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation | Q40353307 | ||
| Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia | Q40399993 | ||
| Braking the cycle | Q40786602 | ||
| Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression | Q40877541 | ||
| Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer | Q40970843 | ||
| Target to apoptosis: a hopeful weapon for prostate cancer | Q41588337 | ||
| The potentiation of adrenaline‐induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects | Q42013212 | ||
| Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance | Q42460153 | ||
| Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. | Q44308840 | ||
| Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit. | Q44646999 | ||
| Cause of death in men diagnosed with prostate carcinoma | Q46270517 | ||
| Alpha1 adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells. Role in mitogenesis | Q46628781 | ||
| Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial | Q46644810 | ||
| Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex | Q46890151 | ||
| Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia | Q46920560 | ||
| Latest frontiers in pharmacotherapy for benign prostatic hyperplasia | Q46976219 | ||
| Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats | Q48702715 | ||
| Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. | Q51456115 | ||
| Lower urinary tract symptoms and risk of prostate cancer in Japanese men. | Q53251467 | ||
| Cell-cycle control and its watchman. | Q53453500 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 444-451 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest | |
| P478 | volume | 122 |
| Q38926248 | 1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1- yloxy)propan-2-ol may be a promising anticancer drug. |
| Q39132093 | 1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1-yloxy)propan-2-ol as a potential anticancer drug |
| Q44968836 | 5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists. |
| Q53281714 | Activity of β2-adrenergic receptor in oral squamous cell carcinoma is mediated by overexpression of the ADRBK2 gene: a pilot study. |
| Q48371276 | Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells |
| Q34575446 | Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells |
| Q39272532 | Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells |
| Q95327767 | Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib |
| Q53749396 | Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells. |
| Q60923881 | Effects of High Concentrations of Naftopidil on Dorsal Root-Evoked Excitatory Synaptic Transmissions in Substantia Gelatinosa Neurons In Vitro |
| Q34166212 | Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport |
| Q49631969 | Human UDP-Glucuronosyltransferase 2B4 and 2B7 Are Responsible for Naftopidil Glucuronidation in Vitro |
| Q41905331 | Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: tubulin-binding drug |
| Q87624906 | Identification of two novel α1-AR agonists using a high-throughput screening model |
| Q34116137 | Long-term α1B-adrenergic receptor activation shortens lifespan, while α1A-adrenergic receptor stimulation prolongs lifespan in association with decreased cancer incidence |
| Q64087771 | Naftopidil reduced the proliferation of lung fibroblasts and bleomycin-induced lung fibrosis in mice |
| Q61806039 | Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G₁ Cell Cycle Arrest |
| Q39163721 | Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor |
| Q38795167 | Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine |
| Q37365172 | Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine |
| Q47646594 | Synthesis and Antitumor Activity of Novel Arylpiperazine Derivatives Containing the Saccharin Moiety. |
| Q58700153 | Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents |
| Q38966404 | Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines. |
Search more.